ACTRN12622000386730招募中1 期
Therapies to prevent progression of COVID-19, including Ivermectin, Doxycycline, Vitamin C, Vitamin D, and Zinc with or without Famotidine: a randomised placebo-controlled double-blind multi-centre outpatient trial
AProf Dr Karin Ried0 个研究点目标入组 300 人开始时间: 2022年3月4日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 40 Years 至 o limit（—）
- 性别
- All
入选标准
- •COVID-19 diagnosis in the preceding 4 days (RAT positive or PCR positive)
- •At least 40 years old
排除标准
- •Women who are pregnant, breastfeeding or actively trying to achieve a pregnancy
- •Current hospital inpatient with COVID-19 related disease
- •Allergy to ivermectin, doxycycline or famotidine
- •Known bleeding disorder
- •Known severe liver disease
- •Diagnosis of Myasthenia Gravis/SLE
- •Consumption of grapefruit juice
- •Ever travelled to countries that are endemic for Loa loa (West and Central Africa – Angola, Cameroon, Central African Republic, Democratic Republic of Congo, Ethiopia, Guinea, Gabon, Republic of Congo, Nigeria and Sudan)
- •Currently on the following medications:
- •oCardiac - quinidine, amiodarone, diltiazem, verapamil, warfarin
- •oAnti-infective – clarithromycin, erythromycin, itraconazole, ketoconazole,
- •oAnti-viral – indinavir, ritonavir, cobicistat
- •oDisease modifying – cyclosporine, tacrolimus, sirolimus, methotrexate
- •oOther – retinoids, lithium, spironlactone
- •Neither minority groups nor NESB/LOTE persons will be excluded provided they possess the capacity (ie ability to understand, retain, comprehend and dutifully consider a response) to consent.
研究者
相似试验
已完成
不适用
International ALLIANCE Study of Therapies to prevent progression of COVID-19, a randomized trialCOVID-19Infection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12620000557932AProf Dr Karin Ried446
撤回
不适用
International ALLIANCE Study of Therapies to prevent progression of COVID-19, a randomized trial - Stage 2COVID-19Infection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12622000309785AProf Dr Karin Ried200
尚未招募
3 期
Prevention and treatment for covid-19 associated severe pneumonia in The Gambia: a randomized clinical trial (PaTS-COVID) COVID-19PACTR202101544570971Medical Research Council Unit The Gambia at LSHTM1,200
进行中（未招募）
2 期
COVID-19 Prevention of worsening of symptoms in asymptomatic to mild patients by combined use of kakkonto and hochuekkito:Exploratory open-label randomized controlled trialCOVID-19JPRN-jRCTs041200072Ogawa Keiko100
尚未招募
不适用
Cord Blood Therapy to prevent progression of COVID-19 related pneumoniaPneumoniaACTRN12620000478910Monash Health24